Glycomine News
September 23, 2026
FDA Grants Breakthrough Therapy Designation to Glycomine’s GLM101 for the Treatment of PMM2-CDG
April 2, 2026
Glycomine Completes Enrollment in Global Phase 2b POLAR Study of GLM101 for the Treatment of PMM2-CDG
September 3, 2025
Glycomine Initiates Dosing in a Global, Randomized, Placebo-Controlled Phase 2b Study of GLM101 for the Treatment of PMM2-CDG
April 16, 2025
Glycomine Announces $115 Million Series C Financing to Advance Lead Drug Candidate, GLM101, into a Phase 2b Clinical Trial for PMM2-CDG
October 10, 2024
Glycomine Appoints Joshua Grass as Chairperson of Board of Directors
September 18, 2024
Glycomine Receives FDA Fast Track Designation for GLM101 for the Treatment of PMM2-CDG
March 4, 2024
Glycomine Announces Encouraging Efficacy Data from Ongoing Phase 2 Clinical Study in PMM2-CDG
December 11, 2023
Glycomine Announces First Pediatric Patient Dosed in Phase 2 Clinical Study of GLM101, a Potential Treatment for PMM2-CDG
November 2, 2023
Glycomine Presents at ASHG 2023 Data from Ongoing Natural History Study with Insight into Genetic Mutations and Biomarkers for PMM2-CDG
October 12, 2023
Glycomine Appoints Dr. Rose Marino Chief Medical OfficerÂ
August 30, 2023